Modality
Small Molecule
MOA
WEE1i
Target
USP1
Pathway
Wnt
RettHS
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
Oct 2021
→ Jun 2025
Phase 1Current
NCT04297614
2,248 pts·HS
2021-10→2025-06·Active
2,248 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-179mo agoInterim· HS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1
Active
Catalysts
Interim
2025-06-17 · 9mo ago
HS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04297614 | Phase 1 | HS | Active | 2248 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR | |
| Motanaritide | Intellia | Approved | PD-1 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 |